Stock Analysis of Redhill Biopharma Ltd (RDHL) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code RDHL
Close 0.396
Change 0.0069 / 1.77 %
Volume 274018
Vol Change -55601.00 / 16.87 %
IndustryDrug Manufacturers-Specialty & Generic
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Very Low Growth Stock
Value Index Very Low Value Stock
Profitability Index Low Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Redhill Biopharma Ltd
PE (TTM)

29.66

Very Poor
Price / Book

-11.34

Very Poor
Price / Sales

9.60

Very Poor
Piotroski F Score

5.0

Indecisive
Market Cap

12622.52 K

Enterprise Value

6981.49 K

ROA (TTM)

8.53

Indecisive
ROE (TTM)

0

Poor
Net Margin (TTM)

32.37

Excellent
Revenue

89.46 %

6513.17 K
Net Profit

133.28 %

23854.37 K
Debt to Equity

0.347

Very Good
Altman Z Score

-28.77

Very Poor
Quick Ratio

0.543

Not Good
Cash Ratio

0.330

Poor


Highs/Lows of Redhill Biopharma Ltd
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.4301 7.91 % 2.10 % 0.43010.374911-Jun-2417-Jun-24
Two Week0.4475 11.49 % 3.59 % 0.50140.374905-Jun-2417-Jun-24
One Month0.4736 16.36 % 3.20 % 0.50140.374905-Jun-2417-Jun-24
Three Month0.5268 24.81 % 6.96 % 0.56390.301-Apr-2416-Apr-24
Six Months1.14 65.25 % 15.98 % 1.740.320-Dec-2316-Apr-24
One year1.99 80.10 % 24.12 % 3.280.25729-Nov-2313-Oct-23
Two year25.44 98.44 % 48.94 % 28.40.25728-Oct-2213-Oct-23
Five year292.8 99.86 % 89.41 % 41.60.25725-Aug-2213-Oct-23
Ten year733.6 99.95 % 181.84 % 888.80.25715-Jun-1513-Oct-23


Technical View of Redhill Biopharma Ltd
RSI

33.92

Neutral
MACD

-0.0163

Bearish
ADX

22.19

Bearish
Super Trend

0.466

Strong Bearish
Williams %R

-83.24

Mild Bullish
CCI

-149.40

Mild Bullish


EMA 5

0.404

Mild Bearish
EMA 15

0.428

Mild Bearish
EMA 50

0.466

Strong Bearish
EMA 100

0.576

Strong Bearish
SMA 100

0.503

Mild Bearish
SMA 200

0.683

Mild Bearish
SMA 5 / 20

0.401 / 0.444

Strong Bearish
SMA 15 / 50

0.438 / 0.446

Strong Bearish
SMA 50 / 200

0.446 / 0.683

Mild Bearish




Charts of Redhill Biopharma Ltd


Returns of Redhill Biopharma Ltd with Peers
Period / StockRDHLFLGCGHSICOSMPIRS
1 Week-7.91%-5.22%-0.496%10.36%-3.10%
1 Mth-16.36%-16.79%17.86%1.01%-11.58%
3 Mth-24.81%-0.909%23.52%-5.55%-28.25%
6mth-65.25%-9.92%78.47%-34.06%-26.56%
1 Year-80.10%-70.22%43.49%-77.81%-86.53%
2 Year-98.44%-92.65%43.29%-93.79%-92.74%
5 Years-99.86%--97.68%-99.28%-97.21%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Redhill Biopharma Ltd with Peers
Ratio / StockRDHLFLGCGHSICOSMPIRS
PE29.66-0.160-2.47-0.237-0.717
P/B-11.340.5091.600.1780.431
ROA8.53-146.99-36.40-40.37-27.31
ROE0-309.38-64.55-75.23-60.11
Debt To Equity0.3470.426000
Revenue6513.17 K
89.46 % 		72416.00 K
94.82 % 		12039.08 K
8.95 % 		49588.25 K
1.51 % 		47357.00 K
82.83 %
Net Income23854.37 K
133.28 % 		-59766.00 K
13.56 % 		-12720.65 K
14.75 % 		-15610.28 K
12.87 % 		-28061.00 K
15.67 %


Technicals of Redhill Biopharma Ltd with Peers
Technical / StockRDHLFLGCGHSICOSMPIRS-
ADX22.1911.4925.8918.8416.25
CMF-0.218-0.3210.3420.161-0.223
MFI43.8421.6075.0630.9853.60
RSI33.9238.3166.3655.1033.39
MACD Abv SignalFalseTrueTrueFalseTrue
Price Above 50 MAFalseFalseTrueTrueFalse-
Price Above 200 MAFalseFalseTrueFalseFalse-


About : Redhill Biopharma Ltd

Address : 21 Ha?arba?a Street, Tel Aviv, Israel, 6473921
Tel : 972 3 541 3131
URL : https://www.redhillbio.com
Code : RDHL, ISIN : US7574681034, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 07_Jan_2013
Employee Count : 53

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.


Note : All Data Generated at the End of Trading Hours (EOD Data)